
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
Patients taking long-term warfarin who had bleeding from their gastrointestinal tract should resume warfarin once the bleeding episode is under control, to reduce their risk of thrombosis.






